Key facts
- This page summarizes Shannon Campbell's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Dec 2024, 16:34.
Shannon Campbell - 13 Dec 2024 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)
- Reporting relationship
- Director
- Issuer ticker
- BDTX
- Reported as of
- 13 Dec 2024
- Net transaction value
- +$11,250
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2024, 16:34:15 UTC
- Prior SEC filing
- 20 Sep 2024
- Next SEC filing
- 12 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Shannon Campbell filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 16 Dec 2024.
Change
- Previous filing in this sequence was filed on 20 Sep 2024.
- Current net transaction value: +$11,250.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BDTX
transaction
Common Stock
Award
- Transaction value
- $11,250
- Shares
- +4,500
- Change %
- +103%
- Price
- $2.50
- Shares after
- 8,865
- Date
- 13 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
Footnote F2
The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024.